Shared on09 Aug 25Fair value Increased 5.80%
Despite a notable reduction in consensus revenue growth forecasts, the analyst price target for Avadel Pharmaceuticals has increased slightly to $18.00. What's in the News Avadel Pharmaceuticals raised full-year 2025 revenue guidance to $265–$275 million and expects Q3 net product revenue of $71–$75 million.
Shared on01 Aug 25
As Avadel Pharmaceuticals’ consensus analyst price target, future P/E, and consensus revenue growth forecasts all remained effectively unchanged, the fair value assessment holds steady at $17.25. What's in the News ASL Strategic Value Fund LP has urged shareholders to vote against Avadel's board nominees and called for an independent election monitor at the upcoming annual meeting, citing concerns about past vote counting procedures.